Medical University of South Carolina, Institute of Psychiatry, Center for Drug and Alcohol Programs
Charleston, South Carolina, 29425, United States
NCT Number: NCT01292057
The purpose of this study is to determine whether aripiprazole (marketed dopamine stabilizer) is effective in reducing of alcohol craving and drinking compared to placebo depending on participant's baseline level of impulsivity.
Looking for future studies?
Notify Me21 year–40 year
All sexes
Interventional
Phase 3
Charleston, South Carolina, 29425, United States
Non-treatment seeking individuals meeting criteria for alcohol dependence (N=120) will be recruited through advertisement and paid for their participation. Subjects will have blood drawn for DNA analysis of various brain dopamine system genes. Alcoholics, after baseline evaluation, will be assigned through urn randomization to one of two experimental groups, depending on their baseline level of impulsivity, in which they will receive either aripiprazole (up to 15 mg/day) or an identical placebo. Subjects will take the study drug or placebo for 8 days (day 1-6 being the natural observation period). After a minimum of 24 hours of abstinence from alcohol (day 7-8) they will undergo an alcohol administration (priming dose) and motivated free choice drinking procedure (on day 8). Alcoholic subjects will receive a brief counseling session at the end of the study to enhance their awareness of problem drinking and to motivate them to seek treatment. Referral for treatment will be offered.
Each subject will undergo a functional MRI (functional magnetic resonance imaging) brain scan with cue stimulation on day 7, on the evening before the alcohol administration paradigm. fMRI (functional magnetic resonance) imaging brain imaging technology will be used to determine if alcoholics treated with aripiprazole differ in alcohol cue-induced activity in the nucleus accumbens. It is hypothesized that aripiprazole will reduce nucleus accumbens activation to alcohol cues compared to placebo.
Whether dopamine system genetic differences will be predict drinking, nucleus accumbens activity, and aripiprazole response will be explored.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion for fMRI (functional magnetic resonance imaging) Imaging:
Exclusion criteria
Aripiprazole(up to 15 mg/day) for 8 days
Other names: Abilify
Placebo to match active drug Aripiprazole for 8 days
Time frame: 6-day observation period
"Natural" alcohol consumption period -- drinks per day consumed during the 6-day observation period
Time frame: 2 hours during the bar lab paradigm
This measure refers to a "bar lab" paradigm in which individuals received an initial "priming" drink of alcohol, targeted to produce a breath alcohol concentration (BrAC) of 30 mg%, and could then choose to consume up to 8 additional drinks, each targeted to produce a BrAC of 15 mg%, during the subsequent 2 hours. Thus, the total number of drinks consumed could range between 0 and 8.
Medical University of South Carolina
Other
Impulsivity and Drinking/Craving: Effect of a Dopamine Stabilizer Medication
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00330486
Alcohol Dependence, Alcohol-Related Disorders
Charleston, South Carolina, United States
View Trial DetailsNCT04007042
Alcohol Dependence, Alcohol-Related Disorders
Nîmes, Gard, France
View Trial DetailsNCT04154111
Alcohol Abuse, Alcohol Dependence
Winston-Salem, North Carolina, United States
View Trial DetailsNCT03952429
Alcohol Abuse, Alcohol Dependence
Lindow, Brandenburg, Germany
View Trial Details